Also found in: Dictionary, Medical, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for diflunisal

nonsteroidal anti-inflammatory (trade name Dolobid) used to treat arthritis and other inflammatory conditions

References in periodicals archive ?
Clinical trial for TTR amyloidosis using diflunisal.
Conjugation-deconjugation cycling of diflunisal via beta-glucuronidase catalyzed hydrolysis of its acyl glucuronide in the rat.
The common NSAIDs still requiring a prescription are naproxen (Naprosyn), piroxicam (Feldene), indomethacin (Indocin), tolmetin sodium (Tolectin), mefenamic acid (Ponstel), diflunisal (Dolobid), and diclofenac sodium (Voltaren).
CRx-401 is a synergistic novel combination containing a sustained-released therapeutic dose of bezafibrate, an anti-cholesterol agent, and a low dose of diflunisal, an analgesic salicylate derivative.
We measured hK5, hK6, and hK11 by sandwich-type ELISA, 96-well plates, as described earlier (19-21) with use of biotinylated detection antibodies, alkaline phosphatase-conjugated streptavidin and diflunisal phosphate substrate.
CRx-401: an interim analysis on the first 50 subjects enrolled in the CRx-401 phase 2 clinical study in Type 2 diabetes indicates that the trial is unlikely to detect a treatment advantage of the CRx-401 combination of bezafibrate and diflunisal over bezafibrate alone.
The plates were washed six times with the wash buffer, and then 100 [micro]L of diflunisal phosphate solution [0.
Merck reported that West Point Pharma's generic formulation of diflunisal exceeded expectations in 1992, accounting for approximately one-half of the dispensed prescriptions for generic diflunisal.
CRx-401 is a synergistic combination drug candidate containing sustained-release bezafibrate, an anti-cholesterol agent approved outside the United States, and a low dose of diflunisal, a widely available analgesic.
We measured the alkaline phosphatase activity by adding the substrate diflunisal phosphate, incubating for 10 min, and then adding a [Tb.
Based on this encouraging preclinical data, CRx-401, a novel synergistic combination containing the cholesterol agent bezafibrate and a low dose of the analgesic diflunisal, has been selected as a clinical product candidate with a phase 2a clinical trial in type 2 diabetes expected to begin mid-2007.
CRx-401 contains the cholesterol agent bezafibrate and a low dose of the analgesic diflunisal, neither of which is indicated for the treatment of diabetes on its own, but which have been shown in preclinical studies to act synergistically to increase insulin sensitivity and lower plasma glucose without causing weight gain.